A Phase 3 interventional study of Tocilizumab and DMARDs in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 38 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-07.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 35th largest by enrollment, is one of 9 that started in 2014, is one of 65 in phase 3, and was the 84th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 9 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 162 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 62nd largest by enrollment of the 141 interventional ones that give a count, is one of 10 that started in 2014, is one of 85 in phase 3, and was the 183rd registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label study will evaluate the efficacy and safety of tocilizumab as monotherapy or in combination with methotrexate or other non-biologic disease modifying anti-rheumatic drugs (DMARDs) in participants with active rheumatoid arthritis (RA) and an inadequate response to current non-biologic DMARD therapy or the first anti-tumour necrosis factor (anti-TNF) agent. Participants will receive tocilizumab 162 milligrams (mg) subcutaneously once a week for 52 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a weekly SC injection of tocilizumab 162 mg as monotherapy for 52 weeks.
Drug: Tocilizumab
Participants will receive a weekly SC injection of tocilizumab 162 mg in combination with methotrexate or other non-biologic DMARDs for 52 weeks.
Drug: Tocilizumab · Drug: DMARDs · Drug: Oral Corticosteroids · Drug: Methotrexate
Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 52 weeks.
Also known as: RoActemra, Actemra
Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study. The study protocol does not specify any particular therapy.
Stable oral corticosteroids doses (≤10 mg/day prednisone or equivalent) are allowed. The study protocol does not specify any additional detail on types of oral corticosteroids.
Methotrexate per investigator's discretion.
Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 2
DAS28 was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joints count, erythrocyte sedimentation rate (ESR; millimeters per hour \[mm/hour\]), and patient's global assessment of disease activity (measured on a 0 to 100 mm Visual Analog Scale \[VAS\] where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR greater than or equal to (≥) 2.6 to less than or equal to (≤) 3.2 implied low disease activity, greater than (\>) 3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and less than (\<) 2.6 implied clinical remission.
Time frame: Baseline, Week 2
Change From Baseline in DAS28-ESR at Week 4
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
Time frame: Baseline, Week 4
Change From Baseline in DAS28-ESR at Week 8
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
Time frame: Baseline, Week 8
Change From Baseline in DAS28-ESR at Week 12
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
Time frame: Baseline, Week 12
Change From Baseline in DAS28-ESR at Week 16
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
Time frame: Baseline, Week 16
Change From Baseline in DAS28-ESR at Week 20
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
Time frame: Baseline, Week 20
Change From Baseline in DAS28-ESR at Week 24
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
Time frame: Baseline, Week 24
Change From Baseline in DAS28-ESR at Week 28
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
Time frame: Baseline, Week 28
Change From Baseline in DAS28-ESR at Week 32
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
Time frame: Baseline, Week 32
Change From Baseline in DAS28-ESR at Week 36
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
Time frame: Baseline, Week 36
Change From Baseline in DAS28-ESR at Week 40
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
Time frame: Baseline, Week 40
Change From Baseline in DAS28-ESR at Week 44
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
Time frame: Baseline, Week 44
Change From Baseline in DAS28-ESR at Week 48
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
Time frame: Baseline, Week 48
Change From Baseline in DAS28-ESR at Week 52
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
Time frame: Baseline, Week 52
Change From Baseline in DAS28-ESR at Early Withdrawal
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
Time frame: Baseline, early withdrawal (up to Week 52)
Number of Participants Achieving an American College of Rheumatology Criteria 20 (ACR20) Response
A participant had an ACR20 response if there was at least a 20 percent (%) improvement, ie, reduction from Baseline, in TJC (68 joints) and SJC (66 joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, averaged to 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either C-reactive protein \[CRP\] or ESR).
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Number of Participants Achieving an ACR50 Response
A participant had an ACR50 response if there was at least a 50% improvement, ie, reduction from Baseline, in TJC (68 joints) and SJC (66 joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, averaged to 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Number of Participants Achieving an ACR70 Response
A participant had an ACR70 response if there was at least a 70% improvement, ie, reduction from Baseline, in TJC (68 joints) and SJC (66 joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, averaged to 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Number of Participants With European League Against Rheumatism (EULAR) Response (Good, Moderate or No Response) Based on DAS28-ESR
DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (VAS: 0 mm=no disease activity to 100 mm=maximum disease activity). DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. The DAS28-ESR based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline \>1.2 with a DAS28 score ≤3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score \>3.2 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score ≤5.1. Participants with change from baseline \>0.6 to ≤1.2 with a DAS28 score \>5.1, or any score with change from baseline ≤0.6, were assessed as non-responders.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal
The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician global assessment of disease activity assessed on 0-10 centimeter (cm) VAS (0 cm= no disease activity and 10 cm= worst disease activity), and CRP in milligrams per liter (mg/L). SDAI total score = 0-86. SDAI ≤3.3 indicates clinical remission, \>3.3 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal
The CDAI is the numerical sum of four outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician's global assessment of disease activity assessed on 0-10 cm VAS (0 cm= no disease activity and 10 cm= worst disease activity). CDAI total score = 0-76. CDAI ≤2.8 indicates clinical remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high (or severe) disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Percent Change From Baseline in Total TJC on 68 Joints at Week 52
Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 68. A reduction in number of tender joints compared to baseline indicates improvement. The outcome is reported as the percent change from baseline to end of treatment (52 weeks).
Time frame: Baseline, Week 52
Change From Baseline in Total TJC on 28 Joints at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal
Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28. A reduction in number of tender joints compared to baseline indicates improvement.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Percent Change From Baseline in Total SJC on 66 Joints at Week 52
Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 66. A reduction in number of swollen joints compared to baseline indicates improvement. The outcome is reported as the percent change from baseline to end of treatment (52 weeks).
Time frame: Baseline, Week 52
Change From Baseline in Total SJC on 28 Joints at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal
Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28. A reduction in number of swollen joints compared to baseline indicates improvement.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Number of Participants Who Achieved Low Disease Activity as Defined by DAS28-ESR ≤3.2
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Number of Participants Who Achieved Remission as Defined by DAS28-ESR <2.6
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR \<2.6 implied clinical remission.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Number of Participants With Non-Biologic DMARD/Corticosteroid Dose Reductions and/or Discontinuation
Results are reported for number of participants who had non-biologic DMARD/corticosteroid dose reductions and/or discontinuation by reasons for dose reductions or discontinuation (safety reasons, discomfort, lack of efficacy, other reasons, and unknown reasons). Participants may be included under more than one reason.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, at early withdrawal (up to Week 52), follow-up Week 4 (up to Week 56), and follow-up Week 8 (up to Week 60)
Percentage of Methotrexate Adherence as Assessed by Methotrexate Adherence Questionnaire
Methotrexate adherence was determined from responses to the question 'Over the last 3 months you were prescribed 12 doses of methotrexate, how many (approximately) have you taken?' Adherence (%) was calculated as: (Approximate number of doses taken/12)\*100.
Time frame: Baseline, Weeks 12, 24, 36, 52, and at early withdrawal (up to Week 52)
Patient Global Assessment of Disease Activity VAS Score
Patient global assessment of disease activity was measured on a 0 to 100 mm horizontal VAS where 0 mm=no disease activity and 100 mm=maximum disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Patient Pain VAS Score
This assessment represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS where 0 mm= no pain to 100 mm= unbearable pain.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
The HAQ-DI questionnaire measures functional status (disability) and health-related quality of life. It measures the participant's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common activities over past week. Each question is evaluated according to the degree of severity on a 4-point scale. Total score for HAQ-DI was the average of all questions and ranges from 0 = without any difficulty to 3 = unable to do.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score
The FACIT-F score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-F score for a total possible score of 0 (worse score) to 52 (better score).
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Number of Participants Compliant to Tocilizumab Treatment as Measured by Diary Cards and Return Records
A diary card was provided to participants to record home injections. Participants were asked to return all empty drug supply boxes, unused pre-filled syringe, and diary cards to the clinic at each visit as a measure of drug accountability and participant compliance. A participant was considered compliant if the participant correctly administered all scheduled doses of SC tocilizumab during the assessment period.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Number of Participants With Anti-Tocilizumab Antibodies
Time frame: Baseline, Weeks 12 and 24, at early withdrawal (up to Week 52), and follow-up visit (8 weeks after last dose of tocilizumab, up to 60 weeks)
Serum Levels of Tocilizumab
Time frame: Baseline, Weeks 12 and 24, at early withdrawal (up to Week 52), and follow-up visit (8 weeks after last dose of tocilizumab, up to 60 weeks)
Serum Levels of Soluble Interleukin-6 Receptors (sIL-6Rs)
Time frame: Baseline, Weeks 12 and 24, at early withdrawal (up to Week 52), and follow-up visit (8 weeks after last dose of tocilizumab, up to 60 weeks)
| Milestone | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Started | 22 | 140 |
| Received at least 1 dose of tocilizumab | 21 | 140 |
| Completed | 7 | 65 |
| Not completed | 15 | 75 |
| Withdrew: Other | 11 | 66 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Participant/legal guardian decision | 1 | 3 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
DAS28 was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joints count, erythrocyte sedimentation rate (ESR; millimeters per hour \[mm/hour\]), and patient's global assessment of disease activity (measured on a 0 to 100 mm Visual Analog Scale \[VAS\] where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR greater than or equal to (≥) 2.6 to less than or equal to (≤) 3.2 implied low disease activity, greater than (\>) 3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and less than (\<) 2.6 implied clinical remission.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline | 5.52 ± 1.014 | 5.53 ± 1.257 |
| Change at Week 2 | -1.41 ± 0.994 | -1.22 ± 1.131 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Change From Baseline in DAS28-ESR at Week 4 | -1.86 ± 1.016 | -2.11 ± 1.215 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Change From Baseline in DAS28-ESR at Week 8 | -2.42 ± 1.352 | -2.62 ± 1.482 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Change From Baseline in DAS28-ESR at Week 12 | -2.33 ± 1.522 | -2.99 ± 1.510 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Change From Baseline in DAS28-ESR at Week 16 | -2.93 ± 1.218 | -3.07 ± 1.532 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Change From Baseline in DAS28-ESR at Week 20 | -3.17 ± 1.346 | -3.13 ± 1.525 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Change From Baseline in DAS28-ESR at Week 24 | -3.28 ± 1.379 | -3.33 ± 1.470 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Change From Baseline in DAS28-ESR at Week 28 | -3.54 ± 1.260 | -3.32 ± 1.552 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Change From Baseline in DAS28-ESR at Week 32 | -3.19 ± 1.418 | -3.54 ± 1.448 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Change From Baseline in DAS28-ESR at Week 36 | -3.57 ± 1.358 | -3.55 ± 1.589 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Change From Baseline in DAS28-ESR at Week 40 | -3.82 ± 1.143 | -3.64 ± 1.524 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Change From Baseline in DAS28-ESR at Week 44 | -3.61 ± 1.325 | -3.65 ± 1.574 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Change From Baseline in DAS28-ESR at Week 48 | -3.54 ± 1.146 | -3.65 ± 1.552 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Change From Baseline in DAS28-ESR at Week 52 | -3.75 ± 1.361 | -3.67 ± 1.592 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Change From Baseline in DAS28-ESR at Early Withdrawal | -2.88 ± 1.236 | -1.63 ± 1.480 |
A participant had an ACR20 response if there was at least a 20 percent (%) improvement, ie, reduction from Baseline, in TJC (68 joints) and SJC (66 joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, averaged to 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either C-reactive protein \[CRP\] or ESR).
| participants | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Week 2 | 6 | 23 |
| Week 4 | 6 | 68 |
| Week 8 | 11 | 69 |
| Week 12 | 10 | 83 |
| Week 16 | 13 | 83 |
| Week 20 | 15 | 86 |
| Week 24 | 15 | 90 |
| Week 28 | 14 | 87 |
| Week 32 | 13 | 89 |
| Week 36 | 12 | 92 |
| Week 40 | 13 | 91 |
| Week 44 | 12 | 88 |
| Week 48 | 12 | 87 |
| Week 52 | 12 | 88 |
| Early withdrawal | 3 | 10 |
A participant had an ACR50 response if there was at least a 50% improvement, ie, reduction from Baseline, in TJC (68 joints) and SJC (66 joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, averaged to 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).
| participants | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Week 2 | 0 | 5 |
| Week 4 | 3 | 20 |
| Week 8 | 6 | 43 |
| Week 12 | 8 | 54 |
| Week 16 | 7 | 62 |
| Week 20 | 9 | 61 |
| Week 24 | 9 | 64 |
| Week 28 | 13 | 68 |
| Week 32 | 8 | 69 |
| Week 36 | 9 | 74 |
| Week 40 | 9 | 71 |
| Week 44 | 10 | 72 |
| Week 48 | 11 | 73 |
| Week 52 | 8 | 73 |
| Early withdrawal | 2 | 4 |
A participant had an ACR70 response if there was at least a 70% improvement, ie, reduction from Baseline, in TJC (68 joints) and SJC (66 joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, averaged to 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).
| participants | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Week 2 | 0 | 0 |
| Week 4 | 1 | 9 |
| Week 8 | 4 | 19 |
| Week 12 | 3 | 30 |
| Week 16 | 3 | 32 |
| Week 20 | 7 | 37 |
| Week 24 | 5 | 38 |
| Week 28 | 6 | 44 |
| Week 32 | 6 | 47 |
| Week 36 | 7 | 48 |
| Week 40 | 8 | 49 |
| Week 44 | 6 | 53 |
| Week 48 | 8 | 56 |
| Week 52 | 7 | 54 |
| Early withdrawal | 2 | 1 |
DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (VAS: 0 mm=no disease activity to 100 mm=maximum disease activity). DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. The DAS28-ESR based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline \>1.2 with a DAS28 score ≤3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score \>3.2 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score ≤5.1. Participants with change from baseline \>0.6 to ≤1.2 with a DAS28 score \>5.1, or any score with change from baseline ≤0.6, were assessed as non-responders.
| participants | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Week 2: No response | 4 | 56 |
| Week 2: Moderate response | 10 | 56 |
| Week 2: Good response | 7 | 25 |
| Week 4: No response | 3 | 22 |
| Week 4: Moderate response | 7 | 58 |
| Week 4: Good response | 11 | 57 |
| Week 8: No response | 1 | 11 |
| Week 8: Moderate response | 9 | 48 |
| Week 8: Good response | 8 | 72 |
| Week 12: No response | 4 | 11 |
| Week 12: Moderate response | 3 | 34 |
| Week 12: Good response | 12 | 83 |
| Week 16: No response | 1 | 9 |
| Week 16: Moderate response | 4 | 30 |
| Week 16: Good response | 13 | 86 |
| Week 20: No response | 0 | 9 |
| Week 20: Moderate response | 5 | 27 |
| Week 20: Good response | 14 | 85 |
| Week 24: No response | 1 | 7 |
| Week 24: Moderate response | 2 | 21 |
| Week 24: Good response | 16 | 89 |
| Week 28: No response | 1 | 5 |
| Week 28: Moderate response | 0 | 24 |
| Week 28: Good response | 18 | 86 |
| Week 32: No response | 1 | 3 |
| Week 32: Moderate response | 2 | 21 |
| Week 32: Good response | 16 | 91 |
| Week 36: No response | 0 | 4 |
| Week 36: Moderate response | 3 | 19 |
| Week 36: Good response | 15 | 91 |
| Week 40: No response | 0 | 2 |
| Week 40: Moderate response | 1 | 15 |
| Week 40: Good response | 16 | 94 |
| Week 44: No response | 0 | 5 |
| Week 44: Moderate response | 2 | 15 |
| Week 44: Good response | 15 | 87 |
| Week 48: No response | 0 | 4 |
| Week 48: Moderate response | 2 | 13 |
| Week 48: Good response | 14 | 90 |
| Week 52: No response | 0 | 5 |
| Week 52: Moderate response | 3 | 12 |
| Week 52: Good response | 12 | 90 |
| Early Withdrawal: No response | 0 | 11 |
| Early Withdrawal: Moderate response | 1 | 8 |
| Early Withdrawal: Good response | 4 | 9 |
The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician global assessment of disease activity assessed on 0-10 centimeter (cm) VAS (0 cm= no disease activity and 10 cm= worst disease activity), and CRP in milligrams per liter (mg/L). SDAI total score = 0-86. SDAI ≤3.3 indicates clinical remission, \>3.3 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline | 31.23 ± 11.892 | 32.33 ± 11.620 |
| Change at Week 2 | -9.80 ± 10.406 | -6.94 ± 9.710 |
| Change at Week 4 | -12.64 ± 10.502 | -13.92 ± 10.666 |
| Change at Week 8 | -19.75 ± 12.978 | -17.21 ± 12.900 |
| Change at Week 12 | -14.65 ± 15.003 | -20.26 ± 12.739 |
| Change at Week 16 | -19.48 ± 9.649 | -21.16 ± 11.945 |
| Change at Week 20 | -23.67 ± 14.015 | -20.50 ± 11.630 |
| Change at Week 24 | -24.31 ± 13.469 | -23.48 ± 12.417 |
| Change at Week 28 | -24.87 ± 12.554 | -23.26 ± 12.418 |
| Change at Week 32 | -22.98 ± 12.850 | -24.94 ± 11.399 |
| Change at Week 36 | -26.32 ± 12.795 | -24.65 ± 11.268 |
| Change at Week 40 | -27.29 ± 13.280 | -25.46 ± 12.210 |
| Change at Week 44 | -27.71 ± 12.851 | -26.08 ± 11.835 |
| Change at Week 48 | -26.83 ± 13.615 | -26.13 ± 11.189 |
| Change at Week 52 | -27.45 ± 14.351 | -26.15 ± 12.791 |
| Change at early withdrawal | -18.94 ± 14.681 | -9.45 ± 12.533 |
The CDAI is the numerical sum of four outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician's global assessment of disease activity assessed on 0-10 cm VAS (0 cm= no disease activity and 10 cm= worst disease activity). CDAI total score = 0-76. CDAI ≤2.8 indicates clinical remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high (or severe) disease activity.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline | 29.69 ± 11.209 | 30.88 ± 10.953 |
| Change at Week 2 | -8.35 ± 10.433 | -5.16 ± 9.323 |
| Change at Week 4 | -11.87 ± 10.062 | -12.26 ± 10.137 |
| Change at Week 8 | -17.74 ± 12.289 | -15.63 ± 11.873 |
| Change at Week 12 | -15.39 ± 14.216 | -18.66 ± 11.895 |
| Change at Week 16 | -20.70 ± 11.694 | -19.51 ± 11.124 |
| Change at Week 20 | -22.19 ± 13.545 | -19.23 ± 11.433 |
| Change at Week 24 | -22.88 ± 12.720 | -21.96 ± 11.825 |
| Change at Week 28 | -23.43 ± 11.573 | -21.48 ± 11.585 |
| Change at Week 32 | -21.55 ± 12.019 | -23.20 ± 10.842 |
| Change at Week 36 | -24.86 ± 11.854 | -23.10 ± 11.263 |
| Change at Week 40 | -25.74 ± 12.488 | -24.01 ± 11.282 |
| Change at Week 44 | -25.42 ± 11.971 | -24.42 ± 11.186 |
| Change at Week 48 | -25.36 ± 12.718 | -24.59 ± 10.645 |
| Change at Week 52 | -25.48 ± 13.049 | -24.42 ± 12.599 |
| Change at early withdrawal | -17.78 ± 14.667 | -8.68 ± 11.909 |
Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 68. A reduction in number of tender joints compared to baseline indicates improvement. The outcome is reported as the percent change from baseline to end of treatment (52 weeks).
| percent change | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Percent Change From Baseline in Total TJC on 68 Joints at Week 52 | -83.12 ± 26.607 | -80.44 ± 41.226 |
Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28. A reduction in number of tender joints compared to baseline indicates improvement.
| tender joints | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline | 10.4 ± 6.46 | 12.9 ± 7.06 |
| Change at Week 2 | -3.4 ± 5.62 | -2.4 ± 5.63 |
| Change at Week 4 | -3.9 ± 5.80 | -5.4 ± 6.14 |
| Change at Week 8 | -6.6 ± 6.41 | -6.4 ± 6.94 |
| Change at Week 12 | -6.0 ± 6.71 | -8.0 ± 7.35 |
| Change at Week 16 | -7.9 ± 6.35 | -8.2 ± 7.05 |
| Change at Week 20 | -8.5 ± 6.59 | -8.3 ± 7.09 |
| Change at Week 24 | -8.3 ± 7.41 | -9.3 ± 7.53 |
| Change at Week 28 | -8.7 ± 6.26 | -9.2 ± 7.04 |
| Change at Week 32 | -7.6 ± 6.64 | -10.1 ± 6.76 |
| Change at Week 36 | -9.4 ± 6.25 | -9.7 ± 7.23 |
| Change at Week 40 | -10.1 ± 6.64 | -10.3 ± 6.74 |
| Change at Week 44 | -9.7 ± 6.46 | -10.4 ± 6.63 |
| Change at Week 48 | -9.6 ± 6.36 | -10.5 ± 6.70 |
| Change at Week 52 | -9.4 ± 7.15 | -10.4 ± 8.01 |
| Change at early withdrawal | -7.0 ± 6.24 | -3.3 ± 7.46 |
Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 66. A reduction in number of swollen joints compared to baseline indicates improvement. The outcome is reported as the percent change from baseline to end of treatment (52 weeks).
| percent change | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Percent Change From Baseline in Total SJC on 66 Joints at Week 52 | -89.31 ± 20.059 | -74.77 ± 66.277 |
Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28. A reduction in number of swollen joints compared to baseline indicates improvement.
| swollen joints | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline | 7.0 ± 4.64 | 5.6 ± 4.43 |
| Change at Week 2 | -2.5 ± 4.31 | -0.8 ± 3.95 |
| Change at Week 4 | -4.2 ± 3.79 | -2.5 ± 3.81 |
| Change at Week 8 | -4.8 ± 4.21 | -3.2 ± 4.40 |
| Change at Week 12 | -4.2 ± 4.37 | -3.8 ± 4.36 |
| Change at Week 16 | -5.3 ± 4.67 | -3.9 ± 4.41 |
| Change at Week 20 | -5.6 ± 5.08 | -4.2 ± 4.60 |
| Change at Week 24 | -5.9 ± 5.12 | -4.7 ± 4.21 |
| Change at Week 28 | -6.4 ± 4.90 | -4.4 ± 4.63 |
| Change at Week 32 | -5.4 ± 5.10 | -4.8 ± 4.37 |
| Change at Week 36 | -6.5 ± 4.57 | -4.9 ± 4.41 |
| Change at Week 40 | -6.6 ± 5.12 | -5.0 ± 4.82 |
| Change at Week 44 | -6.6 ± 5.28 | -5.2 ± 4.71 |
| Change at Week 48 | -6.4 ± 4.83 | -5.0 ± 4.48 |
| Change at Week 52 | -6.3 ± 4.81 | -5.1 ± 4.51 |
| Change at early withdrawal | -5.8 ± 5.59 | -1.7 ± 4.43 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity.
| participants | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline | 0 | 5 |
| Week 2 | 7 | 18 |
| Week 4 | 9 | 30 |
| Week 8 | 3 | 25 |
| Week 12 | 6 | 23 |
| Week 16 | 3 | 20 |
| Week 20 | 3 | 15 |
| Week 24 | 2 | 15 |
| Week 28 | 4 | 15 |
| Week 32 | 5 | 14 |
| Week 36 | 1 | 14 |
| Week 40 | 3 | 14 |
| Week 44 | 5 | 10 |
| Week 48 | 3 | 12 |
| Week 52 | 0 | 11 |
| Early withdrawal | 2 | 4 |
DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR \<2.6 implied clinical remission.
| participants | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline | 0 | 3 |
| Week 2 | 1 | 15 |
| Week 4 | 2 | 34 |
| Week 8 | 5 | 53 |
| Week 12 | 6 | 66 |
| Week 16 | 10 | 72 |
| Week 20 | 11 | 75 |
| Week 24 | 14 | 76 |
| Week 28 | 14 | 73 |
| Week 32 | 12 | 80 |
| Week 36 | 14 | 80 |
| Week 40 | 13 | 81 |
| Week 44 | 10 | 80 |
| Week 48 | 11 | 78 |
| Week 52 | 12 | 80 |
| Early withdrawal | 3 | 7 |
Results are reported for number of participants who had non-biologic DMARD/corticosteroid dose reductions and/or discontinuation by reasons for dose reductions or discontinuation (safety reasons, discomfort, lack of efficacy, other reasons, and unknown reasons). Participants may be included under more than one reason.
| participants | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline: Safety | 0 | 1 |
| Baseline: Discomfort | 0 | 0 |
| Baseline: Lack of efficacy | 0 | 1 |
| Baseline: Other | 0 | 2 |
| Baseline: Unknown | 0 | 0 |
| Week 2: Safety | 0 | 4 |
| Week 2: Discomfort | 0 | 0 |
| Week 2: Lack of efficacy | 0 | 0 |
| Week 2: Other | 0 | 7 |
| Week 2: Unknown | 0 | 0 |
| Week 4: Safety | 0 | 6 |
| Week 4: Discomfort | 0 | 0 |
| Week 4: Lack of efficacy | 0 | 1 |
| Week 4: Other | 1 | 9 |
| Week 4: Unknown | 0 | 1 |
| Week 8: Safety | 0 | 8 |
| Week 8: Discomfort | 0 | 0 |
| Week 8: Lack of efficacy | 0 | 0 |
| Week 8: Other | 1 | 13 |
| Week 8: Unknown | 0 | 1 |
| Week 12: Safety | 0 | 6 |
| Week 12: Discomfort 8 | 0 | 2 |
| Week 12: Lack of efficacy | 0 | 0 |
| Week 12: Other | 2 | 14 |
| Week 12: Unknown | 0 | 0 |
| Week 16: Safety | 0 | 7 |
| Week 16: Discomfort | 0 | 0 |
| Week 16: Lack of efficacy | 0 | 1 |
| Week 16: Other | 2 | 13 |
| Week 16: Unknown | 0 | 0 |
| Week 20: Safety | 0 | 6 |
| Week 20: Discomfort | 0 | 0 |
| Week 20: Lack of efficacy | 0 | 0 |
| Week 20: Other | 2 | 9 |
| Week 20: Unknown | 0 | 1 |
| Week 24: Safety | 0 | 5 |
| Week 24:Discomfort | 0 | 0 |
| Week 24: Lack of efficacy | 0 | 0 |
| Week 24: Other | 1 | 13 |
| Week 24: Unknown | 0 | 1 |
| Week 28: Safety | 0 | 3 |
| Week 28: Discomfort | 0 | 0 |
| Week 28: Lack of efficacy | 0 | 1 |
| Week 28: Other | 1 | 7 |
| Week 28: Unknown | 0 | 0 |
| Week 32: Safety | 0 | 4 |
| Week 32: Discomfort | 0 | 0 |
| Week 32: Lack of efficacy | 0 | 2 |
| Week 32: Other | 1 | 11 |
| Week 32: Unknown | 0 | 0 |
| Week 36: Safety | 0 | 3 |
| Week 36: Discomfort | 0 | 1 |
| Week 36: Lack of efficacy | 0 | 0 |
| Week 36: Other | 2 | 3 |
| Week 36: Unknown | 0 | 0 |
| Week 40: Safety | 0 | 4 |
| Week 40: Discomfort | 0 | 1 |
| Week 40: Lack of efficacy | 0 | 1 |
| Week 40: Other | 1 | 1 |
| Week 40: Unknown | 0 | 0 |
| Week 44: Safety | 0 | 3 |
| Week 44: Discomfort | 0 | 0 |
| Week 44: Lack of efficacy | 0 | 0 |
| Week 44: Other | 0 | 7 |
| Week 44: Unknown | 0 | 0 |
| Week 48: Safety | 0 | 3 |
| Week 48: Discomfort | 0 | 0 |
| Week 48: Lack of efficacy | 0 | 1 |
| Week 48: Other | 1 | 3 |
| Week 48: Unknown | 0 | 0 |
| Week 52: Safety | 0 | 0 |
| Week 52: Discomfort | 0 | 0 |
| Week 52: Lack of efficacy | 0 | 0 |
| Week 52: Other | 0 | 1 |
| Week 52: Unknown | 0 | 0 |
| Early withdrawal: Safety | 0 | 0 |
| Early withdrawal: Discomfort | 0 | 0 |
| Early withdrawal: Lack of efficacy | 0 | 0 |
| Early withdrawal: Other | 1 | 8 |
| Early withdrawal: Unknown | 0 | 0 |
| Follow-up Week 4: Safety | 0 | 0 |
| Follow-up Week 4: Discomfort | 0 | 0 |
| Follow-up Week 4: Lack of efficacy | 0 | 0 |
| Follow-up Week 4: Other | 0 | 2 |
| Follow-up Week 4: Unknown | 0 | 1 |
| Follow-up Week 8: Safety | 0 | 0 |
| Follow-up Week 8: Discomfort | 0 | 0 |
| Follow-up Week 8: Lack of efficacy | 0 | 0 |
| Follow-up Week 8: Other | 0 | 0 |
| Follow-up Week 8: Unknown | 0 | 0 |
Methotrexate adherence was determined from responses to the question 'Over the last 3 months you were prescribed 12 doses of methotrexate, how many (approximately) have you taken?' Adherence (%) was calculated as: (Approximate number of doses taken/12)\*100.
| percentage of methotrexate adherence | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|
| Baseline | 96.82 ± 7.747 |
| Week 12 | 92.92 ± 14.412 |
| Week 24 | 91.54 ± 20.915 |
| Week 36 | 90.14 ± 21.456 |
| Week 52 | 95.28 ± 11.417 |
| Early withdrawal | 90.69 ± 18.367 |
Patient global assessment of disease activity was measured on a 0 to 100 mm horizontal VAS where 0 mm=no disease activity and 100 mm=maximum disease activity.
| mm | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline | 59.6 ± 26.94 | 62.3 ± 20.72 |
| Week 2 | 50.3 ± 24.01 | 54.5 ± 22.12 |
| Week 4 | 46.4 ± 26.43 | 42.3 ± 23.22 |
| Week 8 | 35.8 ± 24.73 | 36.2 ± 24.43 |
| Week 12 | 41.3 ± 27.67 | 32.1 ± 23.91 |
| Week 16 | 29.6 ± 21.59 | 29.2 ± 22.55 |
| Week 20 | 25.7 ± 23.77 | 29.9 ± 22.99 |
| Week 24 | 23.8 ± 19.55 | 26.6 ± 21.92 |
| Week 28 | 23.2 ± 16.47 | 26.7 ± 23.12 |
| Week 32 | 24.0 ± 17.81 | 24.3 ± 21.66 |
| Week 36 | 24.1 ± 19.13 | 22.3 ± 21.86 |
| Week 40 | 22.5 ± 19.31 | 21.4 ± 20.81 |
| Week 44 | 22.7 ± 20.62 | 22.0 ± 22.83 |
| Week 48 | 22.9 ± 23.31 | 18.9 ± 20.57 |
| Week 52 | 20.6 ± 18.96 | 21.4 ± 23.07 |
| Early withdrawal | 30.8 ± 28.78 | 52.4 ± 24.88 |
This assessment represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS where 0 mm= no pain to 100 mm= unbearable pain.
| mm | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline | 50.5 ± 23.78 | 57.5 ± 21.06 |
| Week 2 | 46.1 ± 22.43 | 51.1 ± 22.58 |
| Week 4 | 47.0 ± 26.69 | 42.4 ± 23.80 |
| Week 8 | 37.8 ± 25.75 | 35.3 ± 24.30 |
| Week 12 | 40.9 ± 29.56 | 30.8 ± 23.29 |
| Week 16 | 29.7 ± 20.83 | 26.8 ± 22.61 |
| Week 20 | 27.6 ± 25.48 | 28.6 ± 23.74 |
| Week 24 | 29.9 ± 22.76 | 25.2 ± 22.16 |
| Week 28 | 24.8 ± 19.15 | 25.6 ± 23.18 |
| Week 32 | 25.1 ± 17.92 | 22.6 ± 21.30 |
| Week 36 | 29.6 ± 20.03 | 22.1 ± 21.68 |
| Week 40 | 27.6 ± 22.70 | 20.9 ± 21.24 |
| Week 44 | 26.7 ± 24.25 | 20.0 ± 21.26 |
| Week 48 | 28.6 ± 28.98 | 17.6 ± 19.66 |
| Week 52 | 22.4 ± 19.70 | 19.0 ± 19.83 |
| Early withdrawal | 30.4 ± 29.57 | 51.6 ± 26.03 |
The HAQ-DI questionnaire measures functional status (disability) and health-related quality of life. It measures the participant's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common activities over past week. Each question is evaluated according to the degree of severity on a 4-point scale. Total score for HAQ-DI was the average of all questions and ranges from 0 = without any difficulty to 3 = unable to do.
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline | 1.806 ± 0.5551 | 1.738 ± 0.6406 |
| Week 2 | 1.558 ± 0.7319 | 1.659 ± 0.6210 |
| Week 4 | 1.616 ± 0.7720 | 1.546 ± 0.7351 |
| Week 8 | 1.508 ± 0.7597 | 1.404 ± 0.8115 |
| Week 12 | 1.488 ± 0.9304 | 1.333 ± 0.8272 |
| Week 16 | 1.351 ± 0.9586 | 1.312 ± 0.8621 |
| Week 20 | 1.409 ± 0.9071 | 1.318 ± 0.8608 |
| Week 24 | 1.330 ± 0.8379 | 1.261 ± 0.8915 |
| Week 28 | 1.330 ± 0.9412 | 1.221 ± 0.8730 |
| Week 32 | 1.351 ± 0.8816 | 1.232 ± 0.8870 |
| Week 36 | 1.432 ± 0.9048 | 1.170 ± 0.8757 |
| Week 40 | 1.479 ± 0.8975 | 1.199 ± 0.8908 |
| Week 44 | 1.442 ± 0.9392 | 1.130 ± 0.9206 |
| Week 48 | 1.361 ± 0.9685 | 1.114 ± 0.8815 |
| Week 52 | 1.338 ± 0.9796 | 1.154 ± 0.9187 |
| Early withdrawal | 1.252 ± 1.1232 | 1.756 ± 0.7820 |
The FACIT-F score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-F score for a total possible score of 0 (worse score) to 52 (better score).
| units on a scale | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline | 18.4 ± 11.14 | 24.3 ± 11.55 |
| Week 2 | 23.1 ± 12.37 | 27.9 ± 11.03 |
| Week 4 | 25.1 ± 12.28 | 30.7 ± 12.10 |
| Week 8 | 30.2 ± 11.58 | 32.8 ± 11.91 |
| Week 12 | 28.4 ± 11.71 | 33.7 ± 11.85 |
| Week 16 | 31.3 ± 13.80 | 34.0 ± 12.53 |
| Week 20 | 33.2 ± 13.57 | 34.1 ± 12.05 |
| Week 24 | 33.8 ± 15.28 | 35.3 ± 10.98 |
| Week 28 | 32.9 ± 12.06 | 35.5 ± 11.59 |
| Week 32 | 34.1 ± 12.68 | 36.2 ± 11.32 |
| Week 36 | 30.3 ± 13.62 | 36.8 ± 11.48 |
| Week 40 | 31.7 ± 12.87 | 37.1 ± 11.69 |
| Week 44 | 31.0 ± 14.02 | 37.2 ± 11.75 |
| Week 48 | 31.6 ± 14.63 | 37.9 ± 11.73 |
| Week 52 | 33.4 ± 14.17 | 38.1 ± 11.16 |
| Early withdrawal | 31.3 ± 2.63 | 24.5 ± 12.08 |
A diary card was provided to participants to record home injections. Participants were asked to return all empty drug supply boxes, unused pre-filled syringe, and diary cards to the clinic at each visit as a measure of drug accountability and participant compliance. A participant was considered compliant if the participant correctly administered all scheduled doses of SC tocilizumab during the assessment period.
| participants | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline | 21 | 137 |
| Week 2 | 20 | 126 |
| Week 4 | 20 | 132 |
| Week 8 | 18 | 124 |
| Week 12 | 18 | 121 |
| Week 16 | 19 | 120 |
| Week 20 | 18 | 114 |
| Week 24 | 16 | 107 |
| Week 28 | 19 | 112 |
| Week 32 | 17 | 111 |
| Week 36 | 17 | 105 |
| Week 40 | 16 | 104 |
| Week 44 | 16 | 102 |
| Week 48 | 13 | 107 |
| Week 52 | 16 | 98 |
| Early withdrawal | 4 | 27 |
| participants | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline | 3 | 6 |
| Week 12 | 0 | — |
| Week 24 | 0 | 2 |
| Early withdrawal | 0 | 0 |
| Follow-up visit | 0 | 0 |
| micrograms per milliliter (mcg/mL) | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline | 0.0000 ± 0.0000 | 0.0082 ± 0.09619 |
| Week 12 | 35.3953 ± 22.69069 | 40.2529 ± 21.05801 |
| Week 24 | 53.0416 ± 39.06367 | 43.9047 ± 30.41603 |
| Early withdrawal | 44.7160 ± 38.81521 | 17.6160 ± 22.92477 |
| Follow-up visit | 0.0597 ± 0.10335 | 2.3123 ± 7.40931 |
| nanograms per milliliter (ng/mL) | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Baseline | 43.63 ± 10.947 | 42.40 ± 12.087 |
| Week 12 | 577.42 ± 175.649 | 548.70 ± 131.079 |
| Week 24 | 602.25 ± 158.541 | 521.07 ± 160.464 |
| Early withdrawal | 639.75 ± 99.644 | 327.95 ± 229.481 |
| Follow-up visit | 132.23 ± 93.048 | 125.07 ± 211.038 |
Collected over Baseline up to Week 60. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab Monotherapy | — | 3/21 (14.3%) | 19/21 (90.5%) |
| Tocilizumab in Combination With Methotrexate or Other DMARDs | — | 7/140 (5%) | 135/140 (96.4%) |
| Event | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| PneumoniaInfections and infestations | 1/21 | 0/140 |
| SinusitisInfections and infestations | 1/21 | 0/140 |
| WoundInjury, poisoning and procedural complications | 1/21 | 0/140 |
| VomitingGastrointestinal disorders | 1/21 | 0/140 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/21 | 0/140 |
| Knee arthroplastySurgical and medical procedures | 1/21 | 0/140 |
| Arthritis bacterialInfections and infestations | 0/21 | 1/140 |
| CellulitisInfections and infestations | 0/21 | 1/140 |
| Subcutaneous abscessInfections and infestations | 0/21 | 1/140 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/21 | 1/140 |
| Event | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs |
|---|---|---|
| Lower respiratory tract infectionInfections and infestations | 6/21 | 25/140 |
| NasopharyngitisInfections and infestations | 5/21 | 33/140 |
| Urinary tract infectionInfections and infestations | 5/21 | 16/140 |
| DiarrhoeaGastrointestinal disorders | 2/21 | 32/140 |
| Alanine aminotransferase increasedInvestigations | 2/21 | 31/140 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/21 | 27/140 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/21 | 21/140 |
| HeadacheNervous system disorders | 4/21 | 13/140 |
| NauseaGastrointestinal disorders | 0/21 | 21/140 |
| Upper respiratory tract infectionInfections and infestations | 2/21 | 20/140 |
FAS population included all participants who received at least one dose of SC tocilizumab.
| Age, Continuous(years) | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs | Total |
|---|---|---|---|
| Mean | 53.9 ± 13.63 | 55.3 ± 10.76 | 55.1 ± 11.14 |
| Sex: Female, Male(Participants) | Tocilizumab Monotherapy | Tocilizumab in Combination With Methotrexate or Other DMARDs | Total |
|---|---|---|---|
| Female | 16 | 104 | 120 |
| Male | 5 | 36 | 41 |
Ran from Mar 2014 to primary completion in Aug 2016, 29 months.
Results were first posted in Dec 2018, 2 years 4 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 29 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab